studies, there is little evidence of actual results in humans except in the (initial fee of up to £,), is likely to inhibit such applications. (14) This is an . papers on cannabinoids and cancer have been published. (42). It is also well. Most of the cannabinoids' effects in neural and nonneural tissues rely . Recent studies have shown that CBD reduces cancer cell viability in many . that was conducted on human subjects was a pilot clinical study on nine. Though cannabinoids are clinically used for anti-palliative effects, recent studies open a promising possibility as anti-cancer agents. They have been shown to.
Study for CBD Cancer and Preliminary Results
CBD reduced anxiety in patients with social anxiety subjected to a stressful public speaking task. Early preclinical findings also suggest that CBD may have therapeutic value as a treatment of substance use disorders. CBD reduced the rewarding effects of morphine xxxviii and reduced cue-induced heroin seeking xxxix in animal models. NIDA is supporting multiple ongoing clinical trials in this area.
A review of 25 studies on the safety and efficacy of CBD did not identify significant side effects across a wide range of dosages, including acute and chronic dose regimens, using various modes of administration. Because of this, there is extensive information available with regard to its metabolism, toxicology, and safety.
However, additional safety testing among specific patient populations may be warranted should an application be made to the Food and Drug Administration. This is a critical area for new research.
While there is preliminary evidence that CBD may have therapeutic value for a number of conditions, we need to be careful to not get ahead of the evidence. Ninety-five percent of drugs that move from promising preclinical findings to clinical research do not make it to market.
The recently announced elimination of the PHS review of non-federally funded research protocols involving marijuana is an important first step to enhance conducting research on marijuana and its components such as CBD.
Still, it is important to try to understand the reasons for the lack of well-controlled clinical trials of CBD including: Furthermore, the opportunity to gather important information on clinical outcomes through practical non-randomized trials for patients using CBD products available in state marijuana dispensaries is complicated by the variable quality and purity of CBD from these sources. The NIH recognizes the need for additional research on the therapeutic effects of CBD and other cannabinoids, and supports ongoing efforts to reduce barriers to research in this area.
NIH is currently supporting a number of studies on the therapeutic effects as well as the health risks of cannabinoids. These include studies of the therapeutic value of CBD for:. Endogenous cannabinoids Endogenous cannabinoids which are produced in our body include lipid molecules containing long-chain polyunsaturated fatty acids, amides, esters and ethers that bind to CB1 or CB2 receptors.
Phytocannabinoids Phytocannabinoids are only known to occur naturally in significant quantity in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichomes.
Synthetic cannabinoids Synthetic cannabinoids have been extensively used as a pharmacological agent, both in vitro and in vivo , to obtain more detailed insight of cannabinoid action, in order to evaluate their potential clinical use. Cannabinoid mediated signaling in cancer cells Cannabinoids activate CB1 or CB2 receptor which in turn modulates diverse signaling targets. Table II Role of cannabinoid in different cancers and its associated signaling.
Cannabinoids Anti-cancer effect and its mechanism of action Anandamide 1 Breast cancer: Suppression of nerve growth factor Trk receptors and prolactin receptors Prostate cancer: Attenuates mechanical hyperalgesia HU 1 Prostate cancer: MMPs pathway 3 Skin cancer: Mitogenic at low doses 4 Glioma: Role of cannabinoids in regulation of cancer growth One of the important aspects of an effective anti-tumor drug is its ability to inhibit proliferation of cancer cells.
Cannabinoids and breast cancer Breast cancer is one of the most common human malignancies and the second leading cause of cancer-related deaths in women, and its incidence in the developing world is on the rise [ 40 - 41 ]. Cannabinoids and prostate cancer Prostate cancer is the most common malignancy among men of all races and is one of the leading causes of cancer death in this population.
Cannabinoids and lung cancer Lung cancer has one of the highest mortality rates among cancer-suffering patients. Cannabinoids and skin cancer Melanoma is the mainly cause of skin cancer—related deaths worldwide. Cannabinoids and pancreatic cancer Pancreatic cancer is one of the most aggressive and devastating human malignancies. Cannabinoids and bone cancer Chondrosarcoma and osteosarcoma are the most frequent primary bone cancers [ 89 ].
Cannabinoids and glioma Gliomas are the most important group of malignant primary brain tumors and one of the most aggressive forms of cancer, exhibit high resistance to conventional chemotherapies. Cannabinoids and oral cancer Oral cancer is mainly occurs in the mouth including lips, tongue and throat.
Cannabinoids and head and neck cancer Marijuana smoking increases the incidence of head and neck cancer in young people but its constituent, cannabinoids have anti-tumor properties. Cannabinoids and thyroid carcinoma Thyroid carcinoma is the most aggressive form which occurs in thyroid gland. Role of cannabinoids in pro-metastatic mechanisms like angiogenesis, migration and invasion Migration and invasion are characteristic features of cancer cells.
Role of cannabinoids in stemness and cancer Cancer stem cells CSC are part of the tumor cell population. Role of cannabinoids in immune environment and cancer Cancer is a type of inflammatory disease, where immune cells infiltrate into the tumor site and secrete factors which enhance the prospects of proliferation, angiogenesis and metastasis [ ].
Footnotes The authors disclose no competing interests. Medical use of cannabis. Harvey Lecture, February 19, Bull N Y Acad Med. Cannabis use for chronic non-cancer pain: Cannabinoids for cancer treatment: Functionally selective cannabinoid receptor signalling: Structure of a cannabinoid receptor and functional expression of the cloned cDNA.
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Distribution of cannabinoid receptors in the central and peripheral nervous system. Molecular characterization of a peripheral receptor for cannabinoids. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol. The endocannabinoid system as an emerging target of pharmacotherapy.
Towards the use of cannabinoids as antitumour agents. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat. Neurobiology Cannabinoids act backwards. Ruminska A, Dobrzyn A. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Biochemistry of the endogenous ligands of cannabinoid receptors. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus.
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Chemical characterization of a family of brain lipids that induce sleep. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors.
Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. International Union of Pharmacology. Classification of cannabinoid receptors. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Inhibition of glioma growth in vivo by selective activation of the CB 2 cannabinoid receptor. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor CB2: J Pharmacol Exp Ther.
Binding of the non-classical cannabinoid CP 55,, and the diarylpyrazole AM to rodent brain cannabinoid receptors. SRA, a potent and selective antagonist of the brain cannabinoid receptor. SR , the first potent and selective antagonist of the CB2 cannabinoid receptor. Hanahan D, Weinberg RA. The hallmarks of cancer. Ocana A, Pandiella A. Identifying breast cancer druggable oncogenic alterations: Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data.
Baselga J, Swain SM. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Deltatetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.
Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. The cannabinoid CB1 receptor antagonist rimonabant SR inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
Anandamide inhibits adhesion and migration of breast cancer cells. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.
Homeostatic chemokine receptors and organ-specific metastasis. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression.
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Delta 9 -tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.
Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB 1 Arch Toxicol. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. A high cannabinoid CB 1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer.
Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism.
Involvement in Raf-1 stimulation and NGF induction. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Guindon J, Hohmann AG. The endocannabinoid system and cancer: The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.
Involvement of CB1 cannabinoid receptor and Raf Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent.
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
Anti-proliferative and anti-angiogenic effects of CB2R agonist JWH in non-small lung cancer cells A and human umbilical vein endothelial cells: Folia Biol Praha ; 58 2: Cannabinoid receptors as novel targets for the treatment of melanoma. Cannabinoids in pancreatic cancer: Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.
Cartilage tumours and bone development: Management of bone metastases. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: J Pain Symptom Manage.
Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55, in experimental models of bone cancer pain and neuropathic pain. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. The cannabinoid receptor agonist, WIN 55, , attenuates tumor-evoked hyperalgesia through peripheral mechanisms.
Acute and chronic administration of the cannabinoid receptor agonist CP 55, attenuates tumor-evoked hyperalgesia. Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain. Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM in two models of bone cancer-induced pain. Intrathecal administration of the cannabinoid 2 receptor agonist JWH can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid.
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res. Inhibition of tumor angiogenesis by cannabinoids. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.
A combined preclinical therapy of cannabinoids and temozolomide against glioma. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.
The first experiment that was conducted on human subjects was a pilot clinical study on nine terminal patients with recurrent glioblastoma who were resistant to the standard therapy Patients received THC intratumorally. This way of administration was safe and patients did not exhibit any overt psychoactive effects.
In some patients the tumor growth rate decreased. Changes observed upon THC administration in two patients can be connected with anticancer effect of THC according to previous preclinical studies decreased cell proliferation, occurrence of apoptosis Despite these interesting observations, it is not possible to draw significant conclusions from the study on a group of nine.
This shows a need for further clinical trials, which could help to assess the dosage and the potential interaction of cannabinoids with other substances. These studies are currently ongoing or have ended recently, but the results have not been published to date. Cannabis plants produce a substantial amount of cannabinoids and other secondary metabolites.
It has been demonstrated that extracts of Cannabis exhibit stronger effects on the subjects with spasticity than pure THC Some cannabinoids have been demonstrated to attenuate psychoactive effects of THC or smoked marijuana 13 , Pure cannabinoids are more convenient for study and to a subsequent standardization as a medical preparation, but still Cannabis extracts with specified amounts of cannabinoids seem to be valuable aim for further studies, also as potential anticancer agents.
An interesting idea is a combination of cannabinoids with conventional anticancer drugs, which can exhibit synergistic potential. The promising results from studies on animal models of glioblastoma treated with THC and temozolomide have led to, mentioned above, clinical trial of this chemotherapeutic agent and Sativex 94 , Similar observations from the study on pancreatic adenocarcinoma showed that gemcitabine administered with cannabinoids synergistically inhibited cancer cell growth To date, Cannabis or its preparations have found an application in a palliative medicine due to its analgesic and antiemetic effects, an attenuation of the side effects of chemotherapy or a capacity to treat spasticity in multiple sclerosis.
We are still initial stages of incorporating Cannabis products in the clinical care. There is still a lack of profound safety and efficacy clinical trials and it is very difficult or even impossible to assess the potential benefits and risk of using cannabinoids in many cases. Many aspects wait for an elucidation: The most common way of using recreational marijuana is smoking, which is unsuitable way of an administration from a medical point of view.
Another important issue is the lack of easy accessible biomarkers showing the responsiveness of patients to a cannabinoid treatment. Moreover, antitumor effects of cannabinoids have to overcome their known immunosuppressive effects which can be potentially protumorigenic.
The interactions between cannabinoids and classical cytotoxic agents have to be precisely defined. These observations lead us to the conclusion, that further profound studies are doubtlessly needed to verify the idea of introducing cannabinoids into the cancer treatment.
National Center for Biotechnology Information , U. Journal List Cancer Med v. Published online Feb Author information Article notes Copyright and License information Disclaimer. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This article has been corrected. This article has been cited by other articles in PMC. Abstract To date, cannabinoids have been allowed in the palliative medicine due to their analgesic and antiemetic effects, but increasing number of preclinical studies indicates their anticancer properties.
Introduction Nowadays, we observe an increasing public and scientific interest in the medical applications of Cannabis plants. Endocannabinoid system and cancer Despite numerous studies conducted during the last decade, there are still inconsistent data regarding the exact role of cannabinoid system in cancer development. Open in a separate window.
Cannabinoids and the immune system The mechanism of the immunomodulatory effects of cannabinoids is still not fully elucidated. Selectivity and stimulation of viability Viability of noncancerous cells seems to remain unchanged or sometimes even elevated by cannabinoids 34 , 35 , 36 , 39 , Inhibition of angiogenesis and metastasis Besides the above described proapoptotic effect in cancer cells, cannabinoids exhibit some other important and potentially valuable properties.
Anticancer effects of cannabinoids in clinical trials Data collected to date regarding anticancer effects of cannabinoids are almost completely limited to preclinical studies conducted on cell lines and animal models. Conclusions Cannabis plants produce a substantial amount of cannabinoids and other secondary metabolites. Conflict of Interest The authors declare that they have no conflict of interest. Supporting information Table S1. Click here for additional data file. The use of medical marijuana in cancer.
State Medical Marijuana Laws [Internet]. International union of basic and clinical pharmacology. Cannabinoid receptors and their ligands: Medical marijuana for cancer.
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Molecular characterization of a peripheral receptor for cannabinoids. Cannabinoid pharmacology in cancer research: A new hope for cancer patients?
Towards the use of cannabinoids as antitumour agents. Springer, Berlin, Heidelberg; [cited Jan 4]. Handbook of Experimental Pharmacology. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
Cannabinoids for Medical Use. Anticancer mechanisms of cannabinoids. The use of cannabinoids as anticancer agents.
The current state and future perspectives of cannabinoids in cancer biology
And while it's certainly not a cure, the trial results suggest that cannabinoids are with advanced cancer, and the other is an early-stage trial testing a cannabis. Cannabis has been used medicinally for millennia, but has not been approved by the U.S. Food and Drug Administration to treat any medical. Cannabis, cannabinoids and cancer – the evidence so far So far, the best results from lab studies have come from using a combination of But because this was an early stage trial without a control group, it couldn't show.